OverviewSuggest Edit

Bioventus is a company specializing in orthobiologics and active healing. It provides products for the treatment of bone fractures and chronic pain associated with osteoarthritis. In addition, the company develops orthobiologic surgical solutions for musculoskeletal healing and regeneration.

TypePublic
Founded2012
HQDurham, NC, US
Websitebioventusglobal.com
Employee Ratings3

Latest Updates

Employees (est.) (Sept 2020)680
Job Openings38
Revenue (FY, 2019)$340.1 M(+7%)
Share Price (Sept 2021)$13.9(-2%)
Cybersecurity ratingBMore

Key People/Management at Bioventus

Ken Reali

Ken Reali

Chief Executive Officer
Greg Anglum

Greg Anglum

Senior Vice President and Chief Financial Officer
Anthony D'Adamio

Anthony D'Adamio

Senior Vice President and General Counsel
Katrina Church

Katrina Church

Chief Compliance Officer
John Nosenzo

John Nosenzo

Chief Commercial Officer
Alessandra Pavesio

Alessandra Pavesio

Senior Vice President and Chief Science Officer
Show more

Bioventus Office Locations

Bioventus has offices in Durham, Mississauga and Hoofddorp
Durham, NC, US (HQ)
Carlisle Place, 4721 Emperor Blvd #100
Mississauga, CA
100-2476 Argentia Rd
Hoofddorp, NL
Taurusavenue 31
Show all (4)

Bioventus Financials and Metrics

Bioventus Revenue

Embed Graph
View revenue for all periods
Bioventus's revenue was reported to be $340.14 m in FY, 2019 which is a 6.6% increase from the previous period.
USD

Revenue (Q1, 2021)

81.8m

Gross profit (Q1, 2021)

59.6m

Gross profit margin (Q1, 2021), %

72.8%

Net income (Q1, 2021)

24.5m

EBIT (Q1, 2021)

22.0m

Market capitalization (17-Sept-2021)

788.7m

Closing stock price (17-Sept-2021)

13.9

Cash (3-Apr-2021)

124.2m

EV

849.2m
Bioventus's current market capitalization is $788.7 m.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

292.1m319.2m340.1m

Revenue growth, %

9%7%

Cost of goods sold

292.1m84.2m90.9m

Gross profit

210.0m235.0m249.2m
Quarterly
USDQ1, 2021

Revenue

81.8m

Cost of goods sold

22.2m

Gross profit

59.6m

Gross profit Margin, %

73%
Annual
USDFY, 2018FY, 2019

Cash

42.8m64.5m

Accounts Receivable

72.6m85.1m

Inventories

27.4m27.3m

Current Assets

148.4m183.0m
Quarterly
USDQ3, 2020Q1, 2021

Cash

72.5m124.2m

Accounts Receivable

80.8m89.5m

Prepaid Expenses

12.0m

Inventories

34.7m39.8m
Annual
USDFY, 2018FY, 2019

Net Income

(12.2m)6.3m

Depreciation and Amortization

29.2m30.3m

Inventories

3.3m(1.4m)

Accounts Payable

12.1m6.6m
Quarterly
USDQ3, 2019Q3, 2020Q1, 2021

Net Income

12.5m1.2m24.9m

Depreciation and Amortization

23.0m21.8m7.2m

Inventories

(3.8m)(7.0m)(3.1m)

Accounts Payable

(198.0k)11.6m(14.1m)
Show all financial metrics

Bioventus Operating Metrics

Q3, 2020

Countries

38

Products

11
Show all operating metrics

Bioventus Acquisitions / Subsidiaries

Company NameDateDeal Size
Bioventus Australia Pty Ltd
Bioventus Canada, Ulc
Bioventus Coöperatief U.A.
Bioventus Germany GmbH
Bioventus Holdings LLC
Bioventus LLC
Bioventus UK, Ltd
Exogen, Inc.

Bioventus Revenue Breakdown

Embed Graph

Bioventus revenue breakdown by geographic segment: 10.3% from International and 89.7% from U.S.

Bioventus Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Bioventus Online and Social Media Presence

Embed Graph

Bioventus News and Updates

Bioventus Proceeds with Option Structure Agreement with CartiHeal

DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has elected to make a $50 million escrow payment pursuant to its Option and Equity Purchase Agreement with CartiHeal Ltd., signaling its i…

Bioventus Invests in Trice Medical Minimally Invasive Technologies

Bioventus Also Agrees to OUS Distribution and Co-Development Relationships Bioventus Also Agrees to OUS Distribution and Co-Development Relationships

Dave Crawford Joins Bioventus as Vice President, Investor Relations and Treasurer

DURHAM, N.C., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has appointed Dave Crawford as its Vice President, Investor Relations and Treasurer. Crawford has more than 20 years of experience across …

Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix

The Combination Further Differentiates Bioventus’ Product Portfolio and Accelerates Its Revenue Growth The Combination Further Differentiates Bioventus’ Product Portfolio and Accelerates Its Revenue Growth

Bioventus Launches OSTEOAMP® SELECT Flowable Nationwide

DURHAM, N.C., July 13, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, is launching OSTEOAMP SELECT Flowable, a flowable allograft bone graft substitute solution developed for a variety of patient procedures i…

Bioventus Study Shows Novel Placental Tissue Biologic Candidate Inhibited Inflammatory and Catabolic Responses In Vitro

Demonstrated Significant Reduction of Pain and Cartilage Degeneration in Rat Osteoarthritis Model Demonstrated Significant Reduction of Pain and Cartilage Degeneration in Rat Osteoarthritis Model
Show more

Bioventus Blogs

DUROLANE Among High-Molecular Weight Hyaluronic Acid Treatments Linked to Significant Improvements in Knee Osteoarthritis Pain by American Academy of Orthopaedic Surgeons

DURHAM, NC – September 20, 2021 – Bioventus Inc., (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in innovations for […] The post DUROLANE Among High-Molecular Weight Hyaluronic Acid Treatments Linked to Significant Improvements in Knee Osteoarthritis Pain by American Academy of Orthopaedic …

Bioventus Invests in Trice Medical Minimally Invasive Technologies Bioventus Also Agrees to OUS Distribution and Co-Development Relationships

Bioventus Also Agrees to OUS Distribution and Co-Development Relationships DURHAM, NC – August 25, 2021 – Bioventus Inc. (Nasdaq: BVS) […] The post Bioventus Invests in Trice Medical Minimally Invasive Technologies Bioventus Also Agrees to OUS Distribution and Co-Development Relationships appeared f…

Dave Crawford Joins Bioventus as Vice President, Investor Relations and Treasurer

DURHAM, NC – August 23, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations […] The post Dave Crawford Joins Bioventus as Vice President, Investor Relations and Treasurer appeared first on Bioventus.

Bioventus Reports Second Quarter Results; Updates Full Year 2021 Financial Guidance

DURHAM, NC – August 10, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the Company”), a global leader in innovations for active […] The post Bioventus Reports Second Quarter Results; Updates Full Year 2021 Financial Guidance appeared first on Bioventus.

Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix

The Combination Further Differentiates Bioventus’ Product Portfolio and Accelerates Its Revenue Growth Significantly Expands TAM and Adds Considerable Scale and […] The post Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix appeared first on Bioventus.

Bioventus Inc. Reports Preliminary Second Quarter Net Sales; Updates Full-Year 2021 Net Sales Guidance

DURHAM, NC – July 29, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or “the Company”), a global leader in innovations […] The post Bioventus Inc. Reports Preliminary Second Quarter Net Sales; Updates Full-Year 2021 Net Sales Guidance appeared first on Bioventus.
Show more

Bioventus Frequently Asked Questions

  • When was Bioventus founded?

    Bioventus was founded in 2012.

  • Who are Bioventus key executives?

    Bioventus's key executives are Ken Reali, Greg Anglum and Anthony D'Adamio.

  • How many employees does Bioventus have?

    Bioventus has 680 employees.

  • What is Bioventus revenue?

    Latest Bioventus annual revenue is $340.1 m.

  • What is Bioventus revenue per employee?

    Latest Bioventus revenue per employee is $500.2 k.

  • Who are Bioventus competitors?

    Competitors of Bioventus include Orthofix, Cutera and Medartis Holding.

  • Where is Bioventus headquarters?

    Bioventus headquarters is located at Carlisle Place, 4721 Emperor Blvd #100, Durham.

  • Where are Bioventus offices?

    Bioventus has offices in Durham, Mississauga and Hoofddorp.

  • How many offices does Bioventus have?

    Bioventus has 4 offices.